ArticleCurrent microbiology2025
Efficacy Enhancement of Cefepime with Lemon Leaf-Reduced Silver Nanoparticles against Drug-Resistant Bacteria.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic-resistant bacterial strains and their massive proliferation of infectious diseases present a critical challenge for treatment with conventional antibiotics i.e. cefepime. To address this, the present investigation explores an eco-friendly approach to enhance cefepime's antibacterial efficacy with silver nanoparticles biologically synthesized using lemon leaf extract as a reducing agent. The concentration, functional groups, structural morphology, elemental analysis and crystalline phase purity, all were confirmed through various characterization techniques i.e. UV-Vis, FT-IR, SEM-EDX, and XRD, respectively. Further, antibacterial analysis was carried out through agar well diffusion, MIC and anti-biofilm assay against Gram-positive strain S. aureus (ATCC 25923) and Gram-negative strain E. coli (ATCC 15597), while biosafety potential was investigated via antioxidant, hemolysis and anti-inflammatory assays. The cefepime-conjugated silver nanoparticles (CEF-Ag NPs) exhibited significantly enhanced antibacterial efficacy compared to cefepime itself, showing inhibition zones of 25 ± 0.5 mm (S. aureus) and 22 ± 0.6 mm (E. coli) at MIC value of 100 ± 0.01 µg/mL. In addition, biofilm inhibition assay demonstrated a substantial reduction in biofilm formation, with optical densities decreasing from 0.55 ± 0.03 at 100 µg/mL to 0.20 ± 0.01 at 1000 µg/mL. Biological safety evaluations showed hemolysis rate of 3.5 ± 0.2% at 200 µg/mL. Regarding DPPH radical scavenging, it was observed with 81 ± 0.03% at 125 µg/mL, and 85 ± 0.04% reduction in inflammation at 125 µg/mL. These findings suggested that CEF-Ag NPs have not only enhanced antimicrobial efficacy but it is also biocompatible, making a promising candidate for combating multidrug-resistant bacterial infections.
Indexed as
Identifiers
41379350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.